How J&J’s Ry­bre­vant com­bo stacks up against As­traZeneca’s Tagris­so in EGFR-mu­tat­ed lung can­cer: #ES­MO23

MADRID — John­son & John­son’s com­bi­na­tion treat­ment for a com­mon mu­ta­tion of non-small cell lung can­cer kept can­cer at bay for longer than As­traZeneca’s Tagris­so — the long­time stan­dard of care for these pa­tients — ac­cord­ing to re­sults from a large clin­i­cal tri­al pre­sent­ed at the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy’s an­nu­al meet­ing.

The pos­i­tive MARI­POSA study re­sults, pre­sent­ed Mon­day, led J&J to claim that the com­bi­na­tion “rep­re­sents a new stan­dard of care in pa­tients with first-line, EGFR-mu­tant ad­vanced NSCLC” — though sev­er­al on­col­o­gists ques­tioned the va­lid­i­ty of the state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.